Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,768 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Sanofi Clear all
Not listed Phase 3 Interventional

Synvisc Injections for Lumbar Facet Joint Pain

NCT00325845
View directory record Official record
Conditions
Joint Pain
Interventions
Synvisc viscosupplementation
Procedure
Lead sponsor
Sheltering Arms Physical Rehabilitation Hospitals
Other
Eligibility
30 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2006 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 1 Interventional

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

NCT05282030
View directory record Official record
Conditions
Renal Impairment
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

NCT00034918
View directory record Official record
Conditions
Breast Neoplasms, Metastases, Neoplasm
Interventions
ZD6474
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 16, 2026, 6:07 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 3 Interventional

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation

NCT00174837
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tirapazamine, Cisplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 16, 2026, 6:07 PM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional Results available

Dupilumab in CRSsNP

NCT04678856
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
Interventions
Dupilumab SAR231893, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Roseville, California • Stockton, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Not applicable Interventional

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

NCT00021151
View directory record Official record
Conditions
Leukemia
Interventions
alemtuzumab
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 16, 2026, 6:07 PM EDT
Active, not recruiting Phase 1 Interventional

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

NCT04754945
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Orange, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
82
States / cities
Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 16, 2026, 6:07 PM EDT
Terminated No phase listed Observational

Kidney Information Network for Disease Research and Education

NCT03321604
View directory record Official record
Conditions
ESRD, Fabry Disease, Rare Diseases, Kidney Diseases, End Stage Renal Disease, Genetic Diseases, X-Linked
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 16, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

NCT04659603
View directory record Official record
Conditions
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Interventions
tusamitamab ravtansine, Gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Orlando, Florida • Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

NCT00222469
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
bevacizumab, gemcitabine, oxaliplatin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

NCT00042354
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Pediatric
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
18
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange County, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 16, 2026, 6:07 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Escondido, California • Lancaster, California • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 6:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study on Teriflunomide-exposed Pregnancies

NCT03198351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

NCT00687765
View directory record Official record
Conditions
Glioblastoma
Interventions
bsi-201 plus temozolomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 16, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

NCT00216138
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine, Premedication
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

NCT00360438
View directory record Official record
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome
Interventions
Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

NCT03417102
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, Bypassing agents
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 16, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction

NCT00123565
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Hexadecasaccharide (SR123781A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 16, 2026, 6:07 PM EDT